> ## Content Index > Fetch the complete content index at: https://nexi.fund/llms.txt > Use this file to discover other available public pages before exploring further. # Agentic AI Meets Clinical Trial Protocol Design: When Machines Write the Study Plan - URL: https://nexi.fund/agentic-ai-clinical-trial-protocol-design-2026/ - Published: 2026-07-18T12:30:11.000Z - Updated: 2026-07-18T12:30:11.000Z - Description: Seventy-six percent of Phase I-IV trials require protocol amendments. Agentic AI platforms from ConcertAI, Biorce, and Rivia are changing that — cutting timelines by up to 20 months and amendments by 50%. A look at the new AI-native layer in clinical protocol design. - Author: Nexi.fund Labs - Tags: AI & Infrastructure, #mode-5, #hook-statistic, #track-F Seventy-six percent of Phase I–IV clinical trials require at least one protocol amendment after the study has started. Each major amendment adds months and hundreds of thousands of dollars in cost. For every week a trial is delayed, patients wait longer for therapies that may already exist in a data set somewhere. That number, 76%, comes from the Tufts Center for the Study of Drug Development. It has not budged in a decade. The bottleneck is not science. It is documentation. A single clinical trial protocol runs dozens to hundreds of pages. It defines eligibility criteria, dosing schedules, statistical methods, safety monitoring, and every variable that determines whether a trial generates usable data or gets scrapped halfway through. Writing one takes six to twelve weeks across multiple functional teams. And because the document is static, a PDF delivered to regulators as a finished artifact, any error caught after submission forces a full amendment cycle. That is the problem agentic AI platforms are now being built to solve. ``` TIMELINE: AI in Clinical Trial Protocol Design ───────────────────────────────────────────────────────────── 2020 ──── 2022 ──── 2024 ──── Feb 2026 ──── 2027+ 🔬 🧪 🏗️ ◉ NOW 🔥 NEXT GPT-3 LLMs for Digital Agentic AI Self-optimizing shows protocol protocols platforms protocols that promise drafting go live ship (ACT, adapt in real for text (BMS + at scale Aika 2.0) time generation Faro) (IQVIA) ``` Key inflection points in the transition from static to AI-native clinical protocols, based on press releases, vendor announcements, and Tufts CSDD benchmarks through mid-2026. ## From Static PDF to Structured Data: The First Break The shift began not with AI but with format. In 2022, Bristol-Myers Squibb began working with Faro Health and Evinova to convert static protocol documents into structured, machine-readable data. Instead of a PDF that a human editor had to open and annotate, the protocol became a data model with study objectives, endpoints, and schedules encoded as fields that software could read, compare, and validate against historical trials. The immediate benefit was error reduction: if an endpoint definition contradicted the schedule of assessments, the system flagged it before the document reached a regulator. By 2024, IQVIA and other CROs had begun offering "digital protocol" services at scale. The market for AI-enabled clinical trial software reached $830 million in 2025 and is projected to hit $2.17 billion by 2029, according to market research published in November 2025\. Compound annual growth: 27%. ## The Agentic AI Inflection: Why 2026 Is Different The difference between generative AI and agentic AI is the difference between a writer who produces a draft and an editor who reads the draft, compares it against a database of every similar study conducted in the last decade, identifies the three most likely failure points, and rewrites the relevant sections before the author has finished their coffee. In February 2026, ConcertAI launched Accelerated Clinical Trials (ACT) at the SCOPE Summit in Orlando. Built on the company's proprietary CARAai agentic AI platform, ACT deploys a suite of purpose-built assistants that handle literature review, protocol design, competitive trial analysis, feasibility assessment, site selection, and patient matching as autonomous, coordinated tasks. The headline numbers: ACT can reduce overall trial timelines by 10 to 20 months, cut study design time by up to 50%, and lower protocol amendments by roughly 50%. Each percentage point represents millions of dollars in avoided cost. "Sponsors don't need another isolated tool," Eron Kelly, ConcertAI's CEO, said at launch. "They need an end-to-end solution that identifies bottlenecks and guides next steps." The platform draws on 11 million curated patient records and connects to public sources like PubMed and ClinicalTrials.gov, as well as common trial management systems. The same week, Oracle debuted its own generative AI data tool for life sciences R&D. The major enterprise platforms are treating clinical trial automation as a priority category. ## Startups Enter the Category: Biorce, Rivia, and the New AI-Native Layer ConcertAI is the established player; 75% of the top 30 life sciences organizations are already customers. But the startup pipeline is building fast. Biorce, a Barcelona-based health AI company, closed a $52.5 million Series A in February 2026 led by DST Global Partners, with participation from Norrsken VC and YZR Capital. Biorce's platform, Aika, is an AI-native operating system for clinical development. The company claims it can generate a regulator-ready protocol in 90 seconds with 86% accuracy, trained on a data set of roughly one million clinical trials. Biorce's CEO Pedro Coelho notes that protocol amendments currently add up to €1 million and six weeks in cost per change. Aika is designed to anticipate those failures before the protocol is submitted. Biorce ended 2025 at approximately 200% above its revenue target, and the Series A brings its total funding past $60 million. In March 2026, Zurich-based Rivia raised €13 million in Series A funding led by Earlybird Health for its agentic data platform, which targets the operational complexity of managing trial data across fragmented systems. The round brought Rivia's total funding to roughly €16 million. ## What Agentic AI Actually Changes in Protocol Design The practical difference between a traditional protocol workflow and an agentic one is not just speed. It is the number of feedback loops that get compressed or eliminated. In a conventional process, a medical writer drafts the protocol based on input from clinical scientists, biostatisticians, and regulatory specialists working in parallel. The draft goes to legal, then to ethics committees, then to site investigators. A contradiction between the inclusion criteria and the site's patient population is typically discovered only when the first enrollment attempt fails, months after the document was finalized. An agentic system, by contrast, runs the proposed protocol against real-world patient data sets before the draft leaves the sponsor's building. It surfaces contradictions, flags enrollment bottlenecks, and suggests alternative criteria calibrated to the actual patient population at the selected sites. The site-activation timeline alone, which can run 6 to 12 months in a traditional model, can be reduced by 25 to 50% through automated validation, according to ConcertAI's published metrics. The same logic applies to the trial master file, the regulatory documentation stack, and the electronic clinical outcome assessment builds. Medable, a Palo Alto-based platform company, has been rolling out agentic AI agents across all three domains throughout 2026: a TMF Agent for document management in March, a PI Summary Agent for principal investigator oversight in June, and an Agentic Accelerator Program to help sponsors deploy the technology operationally. At the BIO International Convention in June 2026, a dedicated session on agentic AI in clinical trials drew a standing-room audience, featuring speakers from the FDA, Hippocratic AI, and AIwithCare. The FDA's Acting Director of the Office of Medical Policy, Dianne Paraoan, addressed how the agency is adapting its review frameworks for AI-assisted protocol submissions. ## The Regulatory Dimension: FDA Signals Openness In April 2026, the FDA kicked off an effort to use AI and data science tools to monitor clinical trials in real time, cutting review times for new drugs. The agency's leadership framed the initiative as a step toward keeping US biomedical research competitive. The move follows guidance documents from 2025 that began sketching a regulatory framework for AI-generated clinical content: not yet a formal approval pathway, but a clear signal of direction. For platform companies, the regulatory question is the single largest variable. A protocol drafted by an AI system that cannot explain its reasoning is unlikely to pass an FDA review. That is why ConcertAI, Biorce, and Faro Health all emphasize explainability as a core design requirement. Aika produces "explainable outputs" with full audit trails; ACT's CARAai platform is built on transparent, citation-linked reasoning; Faro Health's Study Designer generates a quantitative impact assessment for every design decision. Biorce's Coelho frames this as a competitive advantage: "Aika employs a mixture of task models. They are all trained to conduct a single task, while working together to create a protocol that is very likely to gain approval from regulators." ## What This Means for Drug Development Economics The cost of bringing a new drug to market has hovered around $1.1 billion for the last decade, with clinical trials accounting for roughly half of that spend. Protocol amendments are a significant driver: each major amendment costs an estimated $400,000 or more when factoring in site-level changes, IRB resubmissions, and enrollment delays. With approximately 60% of protocols undergoing at least one substantial amendment, the aggregate cost runs into the billions across the industry annually. If agentic AI platforms deliver on their stated metrics — 50% fewer amendments, 10 to 20 months shorter timelines, 25 to 50% faster site activation — the math changes not just for individual sponsors but for the industry's overall R&D efficiency. The Tufts CSDD benchmark of 76% amendment rate becomes a baseline to measure against, rather than an accepted cost of doing business. That is assuming the platforms work as advertised at scale, across therapeutic areas and regulatory jurisdictions. The early evidence, including Biorce's 200% revenue overperformance, ConcertAI's Frost & Sullivan recognition as a top AI clinical trial vendor for 2026, and Medable's expanding agent portfolio, suggests the market is betting they will. ## Key Signals to Track 📊 **Key signals to track** FDA issues formal guidance on AI-generated protocol submissions — the single biggest catalyst A major CRO (IQVIA, Labcorp) acquires an AI-native protocol platform — signals category maturity Phase III trial designed and executed entirely through an agentic platform delivers on timeline vs. historical benchmark Patent filings for AI protocol design methods cross 100/year threshold ## Sources [ ConcertAI Launches Accelerated Clinical Trials, Leveraging Agentic AI to Radically Shorten Trial Timelines Press release covering the ACT platform launch at SCOPE 2026, with specific metrics on timeline reduction and amendment prevention. ConcertAI ](https://www.concertai.com/news/concertai-launches-accelerated-clinical-trials-leveraging-agentic-ai-to-streamline-trial-timelines?ref=nexi.fund) Primary source for ACT platform specifications, performance claims, and CEO quote. [ ConcertAI unveils agentic AI tool to cut trial timelines, costs TechTarget analysis of ACT with additional context on market positioning and interview with VP of Product Management. TechTarget ](https://www.techtarget.com/PharmaLifeSciences/news/366638536/ConcertAI-unveils-agentic-AI-tool-to-cut-trial-timelines-costs?ref=nexi.fund) Independent tech press coverage with industry analyst perspective. [ ConcertAI Bets "Agentic AI" Can Fix the Broken Clinical Trial Timeline HIT Consultant article providing the generative vs. agentic AI distinction and market context. HIT Consultant ](https://hitconsultant.net/2026/02/02/rwd-concertai-launches-act-agentic-ai-clinical-trials-2026/?ref=nexi.fund) Healthcare IT analysis framing the shift from generative to agentic AI in clinical trials.